Terry H Landowski

List of Publications by Year
in descending order

32 papers	8,120 citations	361413 20 h-index	434195 31 g-index
32 all docs	32 docs citations	32 times ranked	16980 citing authors

#	Article	IF	Citations
1	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. American Journal of Cancer Research, 2020, 10, 3047-3060.	1.4	3
2	Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Translational Oncology, 2016, 9, 228-235.	3.7	10
3	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
4	Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biology and Therapy, 2015, 16, 43-51.	3.4	50
5	Targeting Integrin Î±6 Stimulates Curative-Type Bone Metastasis Lesions in a Xenograft Model. Molecular Cancer Therapeutics, 2014, 13, 1558-1566.	4.1	36
6	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood, 2014, 124, 1259-1265.	1.4	34
7	The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Investigational New Drugs, 2013, 31, 1616-1625.	2.6	13
8	Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemotherapy and Pharmacology, 2013, 71, 1567-1576.	2.3	31
9	Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells. Molecular Cancer Research, 2012, 10, 392-400.	3.4	25
10	Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. Cancer Chemotherapy and Pharmacology, 2012, 69, 1039-1049.	2.3	12
11	Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology, 2011, 67, 183-192.	2.3	7
12	Inhibition of protein synthesis by imexon reduces HIF-1Î± expression in normoxic and hypoxic pancreatic cancer cells. Investigational New Drugs, 2009, 27, 89-98.	2.6	11
13	Proteasomal inhibition stabilizes topoisomerase IIÎ± protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochemical Pharmacology, 2008, 75, 883-890.	4.4	16
14	Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1109-1117.	2.5	18
15	Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemotherapy and Pharmacology, 2007, 59, 749-757.	2.3	15
16	Correlates of imexon sensitivity in human multiple myeloma cell lines. Leukemia and Lymphoma, 2006, 47, 97-109.	1.3	15
17	Induction of Apoptosis and Cell Cycle Arrest by Imexon in Human Pancreatic Cancer Cell Lines. International Journal of Gastrointestinal Cancer, 2005, 36, 015-028.	0.4	22
18	Mitochondrial-Mediated Disregulation of Ca2+ Is a Critical Determinant of Velcade (PS-341/Bortezomib) Cytotoxicity in Myeloma Cell Lines. Cancer Research, 2005, 65, 3828-3836.	0.9	193

#	Article	IF	Citations
19	New Therapeutic Approaches to Myeloma. , 2004, , 319-353.		0
20	Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-Î¹B (RelB/p50) in myeloma cells. Oncogene, 2003, 22, 2417-2421.	5.9	178
21	Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene, 2003, 22, 7396-7402.	5.9	180
22	Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines. Journal of Immunology, 2002, 168, 2544-2553.	0.8	109
23	Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anti-Cancer Drugs, 2002, 13, 1031-1042.	1.4	21
24	Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6â€“independent mechanism. Blood, 2002, 100, 3333-3343.	1.4	96
25	Inhibition of Bcrâ€“Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene, 2002, 21, 8804-8816.	5.9	127
26	CD95 Antigen Mutations in Hematopoietic Malignancies. Leukemia and Lymphoma, 2001, 42, 835-846.	1.3	27
27	The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Current Opinion in Oncology, 2000, 12, 557-563.	2.4	86
28	Myeloma Cells Selected for Resistance to CD95-Mediated Apoptosis Are Not Cross-Resistant to Cytotoxic Drugs: Evidence for Independent Mechanisms of Caspase Activation. Blood, 1999, 94, 265-274.	1.4	56
29	Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. Immunity, 1999, 10, 105-115.	14.3	1,512
30	Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia. Blood, 1998, 92, 4771-4777.	1.4	148
31	Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis. Blood, 1997, 89, 1854-1861.	1.4	159
32	Mutations in the Fas Antigen in Patients With Multiple Myeloma. Blood, 1997, 90, 4266-4270.	1.4	209